regulatory

News

EFPIA warns EU reforms will hamstring pharma R&D

A trade organisation representing European pharmaceutical companies warned today that the European Commission’s proposed reforms to pharma legislation could result in the

News

X4 cues up FDA verdict in April for WHIM syndrome drug

The FDA has started a priority review of X4 Pharma’s mavorixafor, angling to become the first therapy for the rare disease WHIM syndrome, with a decision due by 30th April

News

EU clears path for Pfizer’s takeover of Seagen

Pfizer’s $43 billion acquisition of antibody-drug conjugate specialist Seagen has been given the go-ahead by the authorities in the EU, clearing a key remaining obstacle t

Market Access

The UK market: A land of new opportunities for medical devic...

The medical device industry landscape is evolving rapidly, driven both by regulatory changes and the quest for innovation.

News

AZ’s Tagrisso plus chemo get fast FDA review for lung cancer

AstraZeneca will hear back from the FDA in the first quarter of next year about its recent filing of Tagrisso in combination with chemotherapy as a first-line treatment fo

News

MHRA pledges two-week review for low-risk clinical trials

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has implemented one part of its plan to reform the regulations governing clinical trials, namely an ini

EFPIA warns EU reforms will hamstring pharma R&D

X4 cues up FDA verdict in April for WHIM syndrome drug

EU clears path for Pfizer’s takeover of Seagen

The UK market: A land of new opportunities for medical devic...

AZ’s Tagrisso plus chemo get fast FDA review for lung cancer

MHRA pledges two-week review for low-risk clinical trials

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

regulatory

Editor's Picks